ClinConnect ClinConnect Logo
Search / Trial NCT06791629

Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation

Launched by BEIJING ANZHEN HOSPITAL · Jan 23, 2025

Trial Information

Current as of July 24, 2025

Not yet recruiting

Keywords

Persistent Atrial Fibrillation Radiofrequency Catheter Ablation Pulsed Field Ablation

ClinConnect Summary

This clinical trial is studying two different treatments for a heart condition called persistent atrial fibrillation, which causes an irregular heartbeat. The treatments being compared are pulsed field ablation and radiofrequency ablation. Both methods aim to help restore a normal heart rhythm and reduce symptoms. The trial will involve adults aged 18 to 80 who are experiencing their first episode of this condition and meet certain health criteria, such as having a specific heart size and no serious underlying health issues.

Participants in the trial will be randomly assigned to either the pulsed field ablation or the radiofrequency ablation group. They will receive the treatment and then be followed for at least 12 months to see how well the treatments work and to check for any side effects. It's important to note that the trial is not yet recruiting participants, and specific health conditions may disqualify someone from joining, such as severe heart or kidney problems, or if they've had certain heart surgeries. This research aims to provide valuable information about the best treatment options for patients with this type of atrial fibrillation.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18-80 years
  • Patients with non-valvular persistent atrial fibrillation undergoing their first catheter ablation (AF duration: 3 months to 3 years)
  • Left atrial diameter on parasternal long-axis view of echocardiogram \< 50 mm
  • Agree to be randomly assigned to the ablation strategy and able to follow up
  • Exclusion Criteria:
  • Atrial fibrillation due to reversible causes
  • LVEF \< 30%
  • Severe congenital heart disease
  • Severe liver or kidney dysfunction (eGFR \< 15, Child-Pugh grade 3), or history of dialysis
  • History of cardiac surgery, such as coronary artery bypass grafting, mechanical valve or prosthetic valve replacement
  • History of pacemaker implantation, left atrial appendage closure, or patent foramen ovale closure
  • Contraindications to oral anticoagulation
  • Contraindications to right or left heart catheterization
  • Pregnancy
  • Life expectancy \< 1 year (e.g., advanced malignancy, end-stage renal disease)
  • Currently enrolled in another trial evaluating medical devices or drugs
  • Other situations where the investigator determines the subject is unsuitable for the study

About Beijing Anzhen Hospital

Beijing Anzhen Hospital is a leading medical institution in China, renowned for its expertise in cardiovascular diseases and comprehensive healthcare services. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and innovation, facilitating the development of new therapies and treatment protocols. With a focus on patient safety and ethical standards, Beijing Anzhen Hospital collaborates with various research entities to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing the understanding of cardiovascular health. Its commitment to excellence in clinical research is underscored by a multidisciplinary team of experienced healthcare professionals and a state-of-the-art facility equipped to support a wide range of clinical investigations.

Locations

Beijing, , China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported